Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.

Wendy L. Osborne,Maria A. V. Marzolini,Eleni Tholouli,Aravind Ramakrishnan,Carlos Bachier,Peter A. McSweeney,David A. Irvine,Michael Zhang,Muhammad Al-Hajj,Martin Pule,Simon Thomas,Maud Jonnaert,Vijay G R Peddareddigari,Nushmia Z. Khokhar,Robert Chen,Kirit M Ardeshna

Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.

2020

Wendy L. Osborne
Maria A. V. Marzolini
Eleni Tholouli
Aravind Ramakrishnan
Carlos Bachier
Peter A. McSweeney
David A. Irvine
Michael Zhang
Muhammad Al-Hajj
Martin Pule
Simon Thomas
Maud Jonnaert
Vijay G R Peddareddigari
Nushmia Z. Khokhar
Robert Chen
Kirit M Ardeshna

8001Background: CD19 directed CAR T cells are effective in patients with r/r DLBCL, however relapses due to CD19 loss or PDL1 upregulation are common. In this study, we evaluate the safety and effi...

Keywords:

Oncology
Internal medicine
CAR T-cell therapy
dual targeting
in patient
Pathology
Pembrolizumab
CD19
Medicine
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations